Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC

The incidence of cancer is closely correlated with age, as 75% of non-small cell lung cancer (NSCLC) patients are aged at least 65 years. The availability of immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic pattern. Limited studies on elderly patients have demonstrated...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Yunye MAO, Shu SHENG, An WANG, Jinzhao ZHAI, Xiangwei GE, Di LU, Jinliang WANG
التنسيق:	Artigo
اللغة:	Chinês
منشور في:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-05-01
سلاسل:	Chinese Journal of Lung Cancer
الموضوعات:	lung neoplasms elderly non-small cell lung cancer immunosenescence immunotherapy immunotherapy combined with low-intensity chemotherapy
الوصول للمادة أونلاين:	http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.10
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!